Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Amer M Zeidan,Gary J Schiller,Tara L Lin,Pamela S Becker,Prapti A Patel,Eunice S Wang,Alexander I Spira,Michaela L Tsai,Maya Ridinger,Peter J Croucher,Mark Erlander,Sandra L Silberman

doi:10.1182/blood-2019-126262

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Amer M Zeidan, Gary J Schiller + Show 10 more

Open Access

https://doi.org/10.1182/blood-2019-126262

Copy DOI

Journal: Blood	Publication Date: Nov 13, 2019
Citations: 2

Affiliation: Minnesota Oncology, The University of Texas Southwestern Medical Center, Yale Cancer Center, University of Kansas, Virginia Cancer Specialists, Roswell Park Cancer Institute, University of California, Los Angeles, University of Washington, Fred Hutch Cancer Center

#Research Funding #Advisory Role + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Full Text